CStone Pharmaceuticals (2616.HK)
CStone Pharmaceuticals
C1 Building
218 Xinghu Street North Block Suzhou Industrial Park
Suzhou 215123
China
86 512 8718 6550
https://www.cstonepharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 164
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jianxin Yang M.D., Ph.D. | CEO, President of R&D and Executive Director | 7.48M | N/A | 1964 |
| Ms. Weicong Ni | CFO & Joint Company Secretary | N/A | N/A | 1991 |
| Ms. Ying Hua Zhang | Senior VP & Chief Operating Officer | N/A | N/A | 1979 |
| Dr. Ngai Chiu Tse M.D., Ph.D. | Senior VP & Chief Scientific Officer | N/A | N/A | 1968 |
| Mr. Michael J. Choi M.B.A. | Chief Commercial & Strategic Officer | N/A | N/A | 1975 |
| Ms. Liao Min | VP & Head of Commercial | N/A | N/A | 1983 |
| Dr. Yujuan La | Senior Vice President of Product Development | N/A | N/A | 1978 |
| Ms. Mei Yee Yung FCIS, FCS | Joint Company Secretary | N/A | N/A | 1965 |
Description
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Corporate Governance
CStone Pharmaceuticals’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
